Inactivating mutations in PTEN (phosphatase and tensin homolog), which has a tumor suppressor function, produce such activation of the PI3K/akt survival pathway, causing resistance to TKIs and anti-human epidermal growth factor receptor-2 (anti-HER2) antibodies (Garrett and arteaga, 2011). This evidence concerns the gene ERBB2 and neoplasm.